Adjuvant T-DM1 Improves iDFS in Phase III HER2+ Breast Cancer Trial

Ado-trastuzumab emtansine (T-DM1; Kadcyla) was found to significantly reduce the risk of invasive disease recurrence or death compared with trastuzumab (Herceptin) as an adjuvant treatment in patients with HER2-positive early breast cancer who have residual disease following neoadjuvant therapy, according to topline findings of the phase III KATHERINE study.

Moreover, 136 of 496 patients crossed over from the lapatinib/capecitabine arm to T-DM1 after the second interim OS analysis.